The viral lytic cycle is an important process in oncolytic virotherapy. Most mathematical models for oncolytic virotherapy do not incorporate this process. In this article, we propose a mathematical model with the viral lytic cycle based on the basic mathematical model for oncolytic virotherapy. The viral lytic cycle is characterized by two parameters, the time period of the viral lytic cycle and the viral burst size. The time period of the viral lytic cycle is modeled as a delay parameter. The model is a nonlinear system of delay differential equations. The model reveals a striking feature that the critical value of the period of the viral lytic cycle is determined by the viral burst size. There are two threshold values for the burst size. Below the first threshold, the system has an unstable trivial equilibrium and a globally stable virus free equilibrium for any nonnegative delay, while the system has a third positive equilibrium when the burst size is greater than the first threshold. When the burst size is above the second threshold, there is a functional relation between the bifurcation value of the delay parameter for the period of the viral lytic cycle and the burst size. If the burst size is greater than the second threshold, the positive equilibrium is stable when the period of the viral lytic cycle is smaller than the bifurcation value, while the system has orbitally stable periodic solutions when the period of the lytic cycle is longer than the bifurcation value. However, this bifurcation value becomes smaller when the burst size becomes bigger. The viral lytic cycle may explain the oscillation phenomena observed in many studies. An important clinic implication is that the burst size should be carefully modified according to its effect on the lytic cycle when a type of a virus is modified for virotherapy, so that the period of the viral lytic cycle is in a suitable range which can break away the stability of the positive equilibria or periodic solutions.
Introduction
Oncolytic virotherapy is an innovative therapeutic strategy to destruct tumors. This idea stemmed from an old tale: evils can destroy evils. Viruses infect tumor cells and replicate themselves in tumor cells. Upon lysis of infected tumor cells, new virion particles burst out and proceed to infect additional tumor cells. This idea was initially tested in the middle of the last century, and merged with renewed interesting over last 20 years due to the technologic advances in virology and in the use of viruses as vectors for gene transfer. (For the history of oncolytic viruses, see [1] .) Oncolytic viruses -viruses that selectively infect and replicate in tumor cells, but spare normal cells -have two types: oncolytic wild viruses that naturally occur with preferential in human cancer cells, and gene-modified viruses engineered to achieve selective oncolysis. The wild type viruses have shown a limited oncolytic efficacy in some preclinical trials, while gene-modified viruses seem to have a great potency of oncolysis [2] [3] [4] . The list of oncolytic viruses is growing (see [5] for a partial list). However, the efficacy of oncolytic virotherapy has not been well established yet. The major challenges are the replicative ability of oncolytic viruses within tumor cells and the spreadability of infections in whole tumors. Although genetic engineering has made possible to modify the viral genome to improve replicative ability of oncolytic viruses, the whole process of the lytic cycle of oncolytic viruses and viral infection spreading affects the outcome of oncolytic virotherapy. (For a review of oncolytic virotherapy, see [6] .)
At molecular level, a great deal of the intracellular viral life cycle has been found out experimentally. The lytic cycle of a virus has six stages. To infect a cell, a virus must enter the cell through the plasma membrane. The virus attaches to a receptor on the cell membrane, and then releases its genetic materials into the cell. These are the first two stages, called adsorption and penetration. The third stage is integration that the host cell gene expression is arrested, and viral materials are embedded into the host cell nucleus. The fourth stage is biosynthesis that the virus uses the cell machinery to make large amount of viral components, and at the meantime, destroys the host's DNA. Then, it enters the last two stages, maturation and lysis. When many copies of viral components are made, they are assembled into complete viruses. The number of the newly formed viruses is call the burst size of the virus. These phages direct production of enzymes that break down the host cell membrane. The cell eventually bursts, and new viruses come out. (For the details of lytic cycle, see the book [7] .) During the lytic cycle, each stage is mediated by a diverse group of proteins, and each stage needs some time to complete [8] [9] [10] [11] . Overall, the burst size and the time period of the intracellular viral life cycle are important factors in viral therapy. Fig. 1 demonstrates the lytic cycle of oncolytic viruses.
At cell population level, many experiments have been conducted to test the outcome of oncolytic virotherapy. Some experiments with animal models have shown good results, and preclinical trials have achieved reasonable statistic results. All those research are still on phases I and II studies [12] [13] [14] [15] . (For a review, see [5] and references therein.)
Oncolytic virotherapy, on the other hand, has provided opportunities for mathematical modeling. In return, mathematical models may help to understand this complicated treatment and to design efficient protocols. Actually, much effort has been devoted to mathematical studies on oncolytic virotherapy. Wu et al. [16, 17] established a mathematical model in terms of partial differential equations (PDEs), which is essentially a radially-symmetric epidemic model with a freely moving boundary. They compared three alternative virus-injection strategies. Tao et al. proved there is a periodic solution for a similar PDE model as Wu's model [18] . We extended Wu's model to include innate immune responses and found the burst size is an important parameter for oncolytic virotherapy [19] . We also observed oscillation phenomena in our model. In order to thoroughly understand oncolytic virotherapy, it is better first to understand the dynamics of oncolytic virotherapy in a relative simple space-free setting. There are actually several works using ordinary differential equations (ODEs) to study the dynamics of oncolytic virotherapy. Wodarz proposed a mathematical model to study how virus-specific lytic CTL response contributes to killing of infected tumor cells [20] . Novozhilov et al. analyzed a ratio-dependent mathematical model for tumor cell population and infected tumor cell populations [21] . Bajzer et al. proposed a mathematical model for recombinant measles viruses. Their model counts free virus population besides tumor cell population and infected tumor cell populations [22] . Komarova et al. studied several possibilities to build mathematical models for oncolytic virus dynamics where only tumor cell population and infected tumor cell population are considered [23, 24] . Based on Bajzer's model, we proposed a common basic mathematical model for oncolytic virotherapy with the parameter burst-size explicitly built in [25] , and found the burst size is an important parameter for the dynamics of oncolytic treatments. However, all those mathematical models for oncolytic virotherapy do not consider the lytic cycle within infected tumor cells. To consider the intracellular viral life cycle, Tian et al. proposed a mathematical model [26] , and found the viral life cycle can induce oscillations. However, this model does not count free virus population and the apoptosis blockade of infected tumor cells.
In this paper, we propose a mathematical model for the dynamics of oncolytic virotherapy with the viral lytic cycle incorporated. As mentioned above, the burst size and the time period of the intracellular viral life cycle are important factors in viral therapy. Theoretically, we will design two parameters b and s to represent the burst size and the time period of the intracellular viral life cycle respectively, and assume these two parameters are constants. For simplicity, we will not model the details of the lytic cycle. Instead, we will use these two parameters to characterize the dynamics of viral therapy. Specifically, the population of infected tumor cells is determined by the populations of tumor cells and free viruses at s unit time ago, and b new viruses add to free virus population once an infected tumor cell bursts. Such, the model is a nonlinear system of delay differential equations. Although the difficulty of analysis of the model, we obtain some analytical results. We also extend and confirm our analysis by numerical study of the model. One striking feature of the model is that the bifurcation value of the period of the viral lytic cycle is determined by the virus burst size. For the burst size, there are two threshold values. Below the first threshold, the system has an unstable trivial equilibrium and a globally stable viral free equilibrium. When the burst size is between two thresholds, the system has an asymptotically stable third interior equilibrium. When the burst size is above the second threshold, there is a functional relation between the bifurcation value of the delay parameter and the burst size. When the period of the lytic cycle is longer than the bifurcation value, the system undergoes Hopf bifurcation and has orbitally stable periodic solutions. However, this bifurcation value becomes smaller when the burst size becomes bigger. This prediction seems reasonable. When viruses have a big burst size, there will be more newly produced free viruses at unit time, and more infections at average. Then, it will need short time to accumulate enough infections to break away the stability of the co-exiting equilibrium for tumor cells, infected tumor cells and free viruses. This viral lytic cycle may explain the oscillation phenomena observed in many studies. An important clinic implication is that the burst size should be carefully modified according to its effect on the lytic cycle when a type of a virus is modified for virotherapy, so that the period of the viral lytic cycle is in a suitable range which can break away the stability of the interior equilibria or periodic solutions.
Mathematical models
In the paper [25] , the basic mathematical model for oncolytic virotherapy was proposed as follows assumptions, the reader is referred to the article [25] .
As we mention in Introduction, this model and all other mathematical models do not incorporate lytic cycle within infected tumor cells. The time to complete the lytic cycle varies. For example, some virus only needs 30 min, some viruses take several hours to complete this process, and some can take days. Therefore, it is necessary and realistic to incorporate the lytic cycle into the oncolytic virotherapy model for its predicted dynamics. Moreover, to build a population model, we assume that the time period of the lytic cycle to be a constant s. Based on the model (2.1), the rate of change of infected tumor cells at time t will be determined by the tumor cell population and free virus at time t À s, namely, xðt À sÞvðt À sÞ. Although the details of the lytic cycle as shown in Fig. 1 will not be incorporated into the model, we will use the lytic cycle time s and burst size to catch the oncolytic process. Based on the model (2.1), a diagram for the dynamic interactions in oncolytic virotherapy within a tumor is given in Fig. 2 .
Because of the apoptosis blockade of infected tumor cells [5] , infected tumor cells will not die until they burst. That is, a death term for infected tumor cells before bursting is not necessary, and all infected tumor cells will burst. Therefore, the model we propose is given by the system (2.2). where
Preliminary results
To study the dynamics of the system (2.3) when s P 0, we need to consider a suitable phase space and a feasible region. For s > 0, let C ¼ Cð½Às; 0; RÞ be the Banach space of continuous functions mapping the interval ½Às; 0 into R with the norm kuðhÞk ¼ sup Às6h60 juðhÞj for u 2 C. The nonnegative cone of C is denoted by C þ ¼ Cð½Às; 0; R þ Þ. We present some preliminary results for the system (2.3). Particularly, when the burst size b is smaller than the first threshold
, the virotherapy fails no matter what the lytic cycle period is.
Proposition 3.1. Suppose that ðxðtÞ; yðtÞ; vðtÞÞ is a solution of system (2.3) with initial conditions xðhÞ ¼ u 1 ðhÞ; yðhÞ ¼ u 2 ðhÞ, and vðhÞ ¼ u 3 ðhÞ, where u i ðhÞ 2 C þ , and u i ð0Þ > 0; i ¼ 1; 2; 3. Then xðtÞ P 0; yðtÞ P 0; vðtÞ P 0 for all t P 0.
Proof. From the first equation of the system (2.3) we have that
Since u 1 ð0Þ P 0, it implies that xðtÞ P 0 for t P 0. When t 2 ½0; s, from the second equation of system (2.3) it follows that
Since u i ðhÞ P 0 ði ¼ 1; 2; 3Þ, we have yðtÞ P 0 when t 2 ½0; s.
From the third equation of system (2.3) we have that
ðk 3 þk 2 xðnÞÞdn yðsÞds ! and u 3 ð0Þ P 0, as well as yðtÞ P 0 for t 2 ½0; s, we have vðtÞ P 0 for t 2 ½0; s. By induction, we have that yðtÞ P 0 and vðtÞ P 0 for all t P 0. Hence the proof is completed. h Proposition 3.2. For the initial conditions in Proposition 3.1, the solutions of system (2.3) are ultimately uniformly bounded in
Proof. By Proposition 3.1, we have that d dt xðtÞ 6 k 1 xðtÞ À k 1 x 2 ðtÞ. By the Comparison Principle, we can get xðtÞ 6 1 when the initial value xð0Þ < 1. Therefore, lim sup t!þ1 xðtÞ 6 1. Furthermore, we consider
and k ¼ minfk 1 ; 1g. We obtain lim sup t!þ1 ½xðt À sÞ þ yðtÞ 6
. Since xðtÞ P 0, we get lim sup t!þ1 yðtÞ 6 . Therefore, xðtÞ; yðtÞ, and vðtÞ are ultimately uniformly bounded in
Proposition 3.2 implies that the x limit set of system (2.3) is contained in the following bounded feasible region:
It is easy to verify that the region M is positively invariant for the system (2.
3). We will analyze the model in this region.
, the system has two equilibria E 0 ¼ ð0; 0; 0Þ, and E 1 ¼ ð1; 0; 0Þ. The E 0 is cancer free equilibrium, and E 1 is infection free but with cancer equilibrium. When b > b c 1 , there is a third equilibrium E Ã ¼ ðx Ã ; y Ã ; v Ã Þ in the feasible range, where
If the burst size b is less than 1, then free viruses will die out eventually. It is impossible to establish any infection within a tumor in this situation. Actually, the burst size is even greater than 1 but smaller than
, it is still impossible for virus infection spreading. At the cancer free and hence virus free equilibrium E 0 ¼ ð0; 0; 0Þ, the eigenvalues of variational matrix of the system (2.3) are
Therefore, this equilibrium is unstable for biologically relevant parameters. Biologically, around the origin, each population has a small size, virus population and infected tumor cell population both decrease, but tumor cell population increases. The instability of this equilibrium is due to the increase of tumor cells. Furthermore, as the tumor population attains its maximal size 1, the equilibrium E 1 ¼ ð1; 0; 0Þ represents failure of the tumor virotherapy. 
Clearly, l ¼ Àk 1 is a root of the Eq. (3.2). So we only need to consider
where
Hence, the roots of (3.3) at s ¼ 0 have negative real parts. This shows that the equilibrium E 1 is locally asymptotically stable when s ¼ 0.
ixðx > 0Þ is a root of (3.3) with s > 0 if and only if
Separating the real and imaginary parts gives 
ð3:4Þ
Adding the squares of both equations together, we obtain
Hence, all the roots of (3.3) have negative real parts when
. Thus, the equilibrium E 1 is locally asymptotically stable for any time delay s P 0. Let
Then we have lim l!þ1 hðlÞ ¼ þ1 and hð0Þ
. It follows that the equation hðlÞ ¼ 0 has at least one positive root. Hence E 1 is unstable for s P 0. h Theorem 3.4. If b < b c 1 , the equilibrium E 1 is globally asymptotically stable for all s P 0.
Proof. Consider a Lyapunov functional on the domain M given by
Vð/Þ ¼ bu 2 ð0Þ þ u 3 ð0Þ þ bk 2 Z 0 Às u 1 ðsÞu 3 ðsÞds:
6 ½k 2 ðb À 1Þ À k 3 u 3 ð0Þ 6 0:
Meanwhile, we have _ Vð/Þ ¼ 0 if and only if u 3 ð0Þ ¼ 0. Thus, the maximum invariant set in f/ 2 Mj _ Vð/Þ ¼ 0g is the singleton E 1 . The classical Lasalle's Invariance Principle [27] implies that E 1 ¼ ð1; 0; 0Þ is globally attractive. This confirms the globally asymptotical stability of E 1 for s P 0. h
Hopf bifurcations and periodic solutions
When the burst size b is greater than the first threshold b c 1 , the system (2.3) has the third interior equilibrium E Ã . There exists the second threshold of the burst size, b c 2 which is greater than b c 1 . When the burst size b is greater than b c 2 , there exists bifurcation value for the lytic cycle period s 0 . When 0 6 s 6 s 0 ; E Ã is locally asymptotically stable. While the system undergoes Hopf bifurcation at s ¼ s 0 . When the lytic cycle period is greater than s 0 , there exists periodic solutions. To study periodic solutions, we compute the directions of Hopf bifurcations, the Floquet exponents of the periodic solutions and their periods. However, we leave the theoretical derivation in Appendix A.
Existence of Hopf bifurcations and periodic solutions
By the transformation
The linearization of (4.1) at ð0; 0; 0Þ is given by
Then the characteristic equation is
It is impossible to find roots of the Eq. (4.3) explicitly. Instead, we look for the condition under which it has purely imaginary roots and there will be Hopf bifurcations. Particularly, we are interested in the condition that relates the burst size b and the delay parameter s. Clearly, ixðx > 0Þ is a root of (4.3) if and only if
Separating the real and imaginary parts, we have
( Adding the squares of both equations together gives
and r ¼ c 
Suppose the Eq. (4.5) has positive roots. Without loss of generality, we assume that it has three positive roots, denoted by z 1 ; z 2 and z 3 , respectively. Then the Eq. (4.4) has three positive roots, say 
Since k 1 k 3 þ k 2 ðb À 1Þ > 0, we obtain /ðbÞ < k 1 À k 3 . From the derivation above, we see that a 1 ðb 1 þ d 1 Þ À ðc 1 þ e 1 Þ > 0 if and only if /ðbÞ < k 1 À k 3 . Therefore, we conclude that all roots of the Eq. (4.8) have negative real parts if and only if /ðbÞ < k 1 À k 3 when b > b c 1 . To summary, we quote a statement from [28] . 
where wðyÞ ¼ Àk
. W and wðyÞ have the same nonzero roots. We only need to study the root distribution of wðyÞ. Consider w 0 ðyÞ ¼ À3k
Since 4k 2 k 3 > 0; w 0 ðyÞ has two roots, and with opposite signs. Say y 1 < 0; y 2 > 0. Since wð0Þ ¼ 2k 1 k 2 3 > 0; wðyÞ ! þ1 as y ! À1, and /ðyÞ ! À1 as y ! þ1, so wðy 1 Þ < 0 and /ðy 2 Þ > 0, there is a root y 3 of wðyÞ ¼ 0 such that wðyÞ < 0 when y > y 3 , while wðyÞ > 0 when 0 < y < y 3 . Since wð Consider the coefficient p of the Eq. (4.5), p ¼ a
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi p 2 À 3q p and
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi p 2 À 3q p , which both are real. Since p > 0; z 2 is negative. So, z 0 must be z 1 . Such, we have
Compare their coefficients, we have z We also need to know the sign of a 0 ðsÞ at s ¼ s 0 , which will tell monotonicity of the function aðsÞ around s 0 . We differentiate both sides of the Eq. (4.3) with respect to s, and obtain
Àls :
Solving for the derivative, we have dl ds
Therefore,
We state the results above as a Theorem 4.3 
Numerical study of Hopf bifurcations and periodic solutions
To demonstrate the model behavior, we simulate the system (2.3). According to data in [19] , we choose a set of parameter values as follows: k 1 ¼ 0:1; k 2 ¼ 0:001; k 3 ¼ 0:01. Since we are interested in how the burst size b and the period of the lytic cycle s influence the virotherapy, we will leave these two parameters as variables. The thresholds of the burst size are determined by other three parameters. We compute b c 1 ¼ 1 þ Fig. 3 . It is easy to observe that s 0 is a decreasing function of b. That means, when the virus burst size is big, the time for the virotherapy to get out the stability of the interior equilibrium is short, and the system may shift to oscillated interaction among three populations.
We take several typical cases to demonstrate the what may happen for the system. When b ¼ 100, we compute s 0 ð100Þ ¼ 13:99. If we take s ¼ 9, the equilibrium E Ã should be asymptotically stable. The Fig. 4 shows this situation.
For b ¼ 100 and s 0 ð100Þ ¼ 13:99, if we take s ¼ 16, we obtain periodic solutions for different initial conditions. Fig. 5 show oscillation of each population over time and oscillated interactions between three populations.
To Study these periodic solutions, we study the directions of bifurcations, the Floquet exponents and periods of bifurcating solutions. The theoretical derivation is given in Appendix A. We compute c 1 ð0Þ ¼ À0:0238 À 0:4238i, hence Refc 1 ð0Þg < 0. We also get Refl 0 ðs 0 Þg > 0; l 2 > 0; b 2 ¼ À0:0476 < 0. Therefore, the positive equilibrium E Ã is asymptotically stable when s 2 ½0; 13:99Þ, the Hopf bifurcation is supercritical and the bifurcating periodic solution is orbitally stable when s > s 0 .
We know from the function wðbÞ that the system will not undergo Hopf bifurcations around E Ã when the value of b choose
On the other hand, we choose the burst size b as a bifurcating parameter. We fix the lytic cycle period, say s ¼ 8, according to the relation between s 0 and b as shown in Fig. 3 , we obtain b Ã % 133. To demonstrate, we take two different values of the burst size, b ¼ 100 and b ¼ 150. Fig. 6 shows the positive equilibrium E Ã is asymptotically stable.
When the burst size b ¼ 150 > 133, we have periodic solutions for different initial conditions. Fig. 7 shows the dynamics of each population over time and interactions among them. We also did computation in Appendix A, and find these Hopf bifurcations are supercritical and the bifurcating periodic solutions are orbitally stable.
In summary, when the burst size b and the lytic cycle s are above the bifurcation curve in Fig. 3 , the system has periodic solutions. When b and s are below the bifurcation curve and b > b c 2 , the system has the stable interior equilibrium solution.
Along the bifurcation curve, the system undergoes Hopf bifurcations.
Summary and discussion
The viral lytic cycle is the most important process in oncolytic virotherapy. tal or clinical results, and even cannot establish a meaningful infection. Therefore, the understanding of the viral lytic cycle within a tumor is essential for improving experimental and clinical efficacy of virotherapy. The dynamics of the viral lytic cycle can be described by two parameters, the viral burst size and the time period of the viral lytic cycle. In this article, we study the viral lytic cycle by applying delayed differential equations. The model is a nonlinear system of three differential equations. It explicitly incorporates the burst size b and the period of the viral lytic cycle s. Recalling the ODE model [25] which does not have the period of the viral lytic cycle as a delay parameter, the dynamics is easier to characterize but may be insufficient to the real therapy. Concretely, in [25] , it is shown that there also exist two threshold values for the burst size. Below the first threshold, the system has a globally asymptotically stable virus free equilibrium, this result also occurs in our present model (2.2), which means under this condition the virus-free equilibrium E 1 is robust [23] ; while passing this threshold, there is a locally stable positive equilibrium. Above the second threshold, there exits one or three families of periodic solutions arising from Hopf bifurcations. Comparing with the model with more details of the viral lytic cycle, namely the period of the viral lytic cycle included in the present paper, the delay parameter of the period of the viral lytic cycle makes the model more realistic although the burst size seems to be a major parameter to determine the outcome of the virotherapy. This may provide more realistic suggestions for experimental and/or clinical virotherapy than the ODE model and the other simple ones. As mentioned in Introduction, two types of viruses have been applied in experiments and/or clinical virotherapy, oncolytic wild viruses and gene-modified viruses. There are various genetic methods that can be used to modify the genomes of viruses so that the viruses have desired burst sizes [6] . For different viruses, their burst sizes may be modified according to their nature to obtain new viruses with various burst sizes. As we demonstrated, the burst size has effects on the period of viral lytic cycle, and thus affects the outcome of the virotherapy. It is clear that any oncolytic virus with small burst size, say smaller than the first threshold, can not eradicate the tumor, in stead, the tumor will grow to its maximum volume. When oncolytic viruses have a medium burst size, the outcome of the virotherapy could be the coexistence of three populationstumor cell population, infected tumor cell population, and virus population, and this is determined by the period of the lytic cycle. When oncolytic viruses have large burst size, the outcome of the virotherapy could be the coexistence of three populations or the oscillation of three population. If viruses have huge burst size, the period of the viral lytic cycle will have less effect, and the averages of each population will have a small portion although most outcome will be oscillations of three populations. Since the success of the therapy is determined by detectability of tumor cells, it will be reasonable to apply oncolytic viruses with big burst size in the treatments. However, the stability in each case, coexistence and oscillations, should be broken away when the solution tends to reduce the amount of tumor cells. Overall, a clinic implication is that the period of the viral lytic cycle and the viral burst size should be modified simultaneously when a type of a virus is modified for oncolytic virotherapy, so that the period of viral lytic cycle and burst size are in a suitable range which can produce a desired outcome.
As a theoretical implication, the appearance of periodic solutions in the model with viral lytic cycle included may explain the periodic phenomena observed in [12, 20, 22] and other works. In [22] , the model is for a specific virus measles and it has extra term for cell-to-cell fusion. Although the oscillation was observed, the authors attribute it to some combined parameter which do not have a clear biological significance. In [20] , the models have immune cell population. The author had pointed out that the oscillation may caused by the interaction between immune cells and tumor cells. In other works, for example, in papers [21, 23, 24] , the models only have two populations, tumor cells and infected tumor cells. Although some unstable oscillations were observed in some of those models, we could not figure out a clear biological meaning. In our recently accepted work [26] , we considered a quasi-equilibrium state study where we did not have free virus. We observed oscillation phenomenon. However, we could not explain the relation between the threshold values of s and the burst size b. In our current work, our conclusion seems reasonable in terms of explaining biological observations in [12] . Comparing with all existing models for viral therapy, our current model reveals a striking feature that the critical value of the period of the viral lytic cycle is determined by the viral burst size. An important clinic implication is that the burst size should be carefully modified according to its effect on the lytic cycle when a type of a virus is modified for virotherapy, so that the period of the viral lytic cycle is in a suitable range which can break away the stability of the positive equilibria or periodic solutions.
where 
where qðhÞ is the eigenvector of Að0Þ corresponding to ix 0 , and q Ã ðsÞ is the eigenvector of A Ã corresponding to Àix 0 . 
We We know that (see [29] ) l 2 determines the directions of the Hopf bifurcation: if l 2 > 0 ð< 0Þ, the bifurcating periodic solutions exists in a right (left) neighborhood of s 0 ; b 2 determines the stability of the bifurcating periodic solutions: the bifurcating periodic solutions are orbitally stable (unstable) if b 2 < 0 ð> 0Þ; and T 2 determines the period of the bifurcation periodic solutions: the period increase (decrease) if T 2 > 0 ð< 0Þ.
